|
Market Closed -
London S.E.
11:35:01 2026-09-21 am EDT
|
5-day change | 1st Jan Change | ||
| 1,911.00 GBX | +1.78% |
|
+3.05% | +4.74% |
| Sep. 21 | European Equities Traded in the US as American depositary Receipts Rise in Monday Trading | MT |
| Sep. 21 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| Market Cap | 76.57B 102B 89.28B 84.08B 144B 9,809B 144B 1,007B 388B 4,997B 385B 376B 16,125B | P/E 2026 * |
14.7x | P/E 2027 * | 12.2x |
|---|---|---|---|---|---|
| Enterprise Value | 97.26B 130B 113B 107B 182B 12,459B 183B 1,279B 493B 6,347B 488B 478B 20,480B | EV / Sales 2026 * |
2.87x | EV / Sales 2027 * | 2.66x |
| Free-Float |
92.75% | Yield 2026 * |
3.64% | Yield 2027 * | 3.92% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | +1.78% | ||
| 1 week | +3.05% | ||
| Current month | +3.10% | ||
| 1 month | -0.39% | ||
| 3 months | -0.75% | ||
| 6 months | -2.03% | ||
| Current year | +4.74% |
| 1 week | 1,852.5 |  | 1,916 |
| 1 month | 1,770 | | 1,923 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,455 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/9/26 | Free | Compliance Officer | 7 | 0.0000% | ||
| 9/9/26 | Buy | Executive/Senior Manager | 7 | 0.0000% | ||
| 9/9/26 | Free | Executive/Senior Manager | 7 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.78% | +3.05% | +27.70% | +24.85% | 101B | |
| +1.04% | +2.34% | +54.91% | +111.75% | 1,028B | |
| -0.19% | +1.18% | +52.94% | +66.69% | 651B | |
| +0.20% | +1.04% | +18.88% | +72.38% | 466B | |
| +2.24% | +0.94% | +37.61% | +45.31% | 346B | |
| +0.90% | +1.95% | +18.79% | +25.27% | 266B | |
| +0.48% | +3.34% | +11.11% | +15.38% | 259B | |
| +1.95% | +3.06% | +37.75% | +45.93% | 208B | |
| -7.65% | -7.28% | -33.09% | -59.52% | 191B | |
| +0.30% | +2.83% | +31.97% | +100.03% | 186B | |
| Average | +0.20% | +3.22% | +25.86% | +44.81% | 370.24B | |
| Weighted average by Cap. | +0.59% | +2.61% | +35.35% | +64.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.93B 45.38B 39.56B 37.26B 63.62B 4,347B 63.7B 446B 172B 2,214B 170B 167B 7,146B | 35.5B 47.47B 41.39B 38.99B 66.57B 4,548B 66.65B 467B 180B 2,317B 178B 174B 7,476B |
| Net income | 5.35B 7.15B 6.23B 5.87B 10.03B 685B 10.04B 70.33B 27.11B 349B 26.86B 26.27B 1,126B | 6.28B 8.4B 7.33B 6.9B 11.78B 805B 11.8B 82.64B 31.85B 410B 31.56B 30.86B 1,323B |
| Net Debt | 20.68B 27.65B 24.11B 22.71B 38.78B 2,649B 38.82B 272B 105B 1,350B 104B 102B 4,355B | 17.97B 24.03B 20.95B 19.73B 33.69B 2,302B 33.73B 236B 91.07B 1,173B 90.25B 88.25B 3,784B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-21 | GBX 1,911.00 | +1.78% | 6,861,875 |
| 26-09-18 | GBX 1,877.50 | -1.18% | 15,668,959 |
| 26-09-17 | GBX 1,900.00 | +1.85% | 9,894,223 |
| 26-09-16 | GBX 1,865.50 | +0.62% | 7,165,786 |
| 26-09-15 | GBX 1,854.00 | -0.03% | 4,902,189 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
